Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, was founded in 2004 with the goal of improving the safe use of pharmaceuticals by providing a global, state-of-the-art research model for proprietary (brand name and line extension) and nonproprietary (USAN/INN) pharmaceutical and healthcare nomenclature. Among its many services, DSI offers a medication error prevention analysis associated with labeling of pharmaceuticals, biological products and medical devices, as well various risk management strategies and regulatory submission deliverables.
DSI’s Leadership Team (see below) is comprised of full-time experts who formerly served as key naming, packaging and labeling regulatory officials at FDA, EMA, Health Canada, AMA and WHO. In their former roles, many of our regulatory experts ed the name safety guidance currently in use at their respective agencies. Our DSI Experts have played a key role in making Brand Institute #1 in drug naming worldwide with 14 consecutive years holding a majority global Share of Market Regulatory Name Approvals.
DSI’s methodology for proprietary name safety testing is in full compliance with FDA, EMA, Health Canada, Japan’s Ministry of Health, Labour and Welfare and all other global regulatory agencies for which we provide name safety research.
For immediate regulatory support, contact your local Brand Institute office at the bottom of this page.